Effect of oral pre-meal administration of betaglucans on glycaemic control and variability in subjects with type 1 diabetes

Research output: Contribution to journalArticle


We conducted a double-blind placebo-controlled crossover pilot study to investigate the effect of oat betaglucans (β-glucan) on glycaemic control and variability in adults with type 1 diabetes (T1D; n = 14). Stomacol® tablets (1.53 g of β-glucan) or placebo (Plac) were administered three times daily before meals for two weeks. Glucose levels were monitored during the second week by continuous glucose monitoring (CGM). There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for Plac and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for Plac and β-glucan, p = 0.003) favouring Plac over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures. Basic measures of glucose variability were also slightly increased during β-glucan treatment, with no difference in more complex measures. However, glycaemic variability increased between the first and last two CGM days on Plac, but remained unchanged on β-glucan. In conclusion, in this pilot study we were unable to demonstrate a general positive effect of β-glucan before meals on glucose control or variability in T1D.


External organisations
  • Skåne University Hospital
  • Steno Diabetes Center Copenhagen
  • CNR Institute of Neuroscience, Pisa
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
  • Nutrition and Dietetics


  • Betaglucan, Diabetes, Glucose control, Glucose variability, Viscous fiber
Original languageEnglish
Article number1004
Issue number9
Publication statusPublished - 2017 Sep 12
Publication categoryResearch